O‘zbekiston кardiologiyasi 2-том 3-нөмір (2025) · 202-211-беттер
Influence of combined pathogenetic treatment on the dynamics of epicardial fat thickness in patients with cad and metabolic syndrome
Kim, Andrey, Shek, Aleksandr, Alieva, Rano, Ким, Андрей, Шек, Александр, Алиева, Рано, Kim, Andrey, Shek, Aleksandr, Aliyeva, Rano
Аңдатпа
Aim. To evaluate the influence of combined hypolipidemic therapy (statins in combination with ezetimibe and fenofibrate) and sodium-glucose cotransporter 2 inhibitors on epicardial fat thickness in patients with coronary heart disease and metabolic syndrome. Materials and methods: The study included 49 patients with coronary heart disease and metabolic syndrome who underwent treatment at the Republican Specialized Scientific and Practical Medical Center of Cardiology. The patients were divided into 2 groups: 1) intensive statin therapy in combination with ezetimibe, 2) with the addition of fenofibrate and SGLT2 inhibitors. All patients underwent biochemical tests and imaging marker assessments, followed by comparison of the dynamics within and between groups. Results. When comparing two groups receiving different types of therapy, both groups demonstrated a significant decrease in lipid parameters: LDL-C p<0.001, TC p<0.001, TG p<0.001. Additionally, the group treated with fenofibrate and SGLT2 inhibitors showed a more significant reduction in epicardial fat (11.4 mm in the first group and 10.4 mm in the second group, p<0.05). Conclusion: Pathogenetic therapy with the inclusion of fenofibrate and SGLT2 inhibitors more effectively reduces the level of EFT, as well as TG, VLDL-C, and the TG/HDL index.
coronary artery diseaseepicardial fat thicknesssodium glucose co-transporter 2 inhibitorsmetabolic syndromefenofibrateтолщина эпикардиального жираишемическая болезнь сердцаингибиторы натрий глюкозного котранспортера 2метаболический синдромфенофибрат
Метадеректер дереккөзі: журналдың OAI-PMH архиві · Sindex толық мәтінді сақтамайды, дереккөзге сілтеме береді.